Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Study CQMF149A2210 evaluated the safety of QMF149 Twisthaler® 500/400 μg, a fixed dose
combination of indacaterol 500 μg, a once daily β2 agonist, and mometasone furoate 400 μg, an
inhaled corticosteroid (ICS) that is approved for use in the treatment of asthma. The
objective of this safety trial was to assess the effect of treatment on the incidence of
serious asthma exacerbations, defined as asthma related hospitalization and/or intubation
and/or death. This was an event driven trial.